Statement: Updates to Mirati Therapeutics Executive Leadership Team

San Diego - November 1, 2021 - Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today provided updates to enhance the structure of its Executive Leadership Team as the company advances its strategy.

Following the appointment of David Meek as chief executive officer (CEO) in September 2021, Daniel Faga will step down from his role as executive vice president and chief operating officer. The Company will establish the role of chief financial officer (CFO) to support the expansion of its commercialization capabilities and expanding portfolio, and has begun a search process.

In addition, following Dr. Charles Baum's recently named position as the Company's president, founder and head of research and development, Joseph Leveque, M.D. will step down from his role as executive vice president and chief medical officer.

The Company's Executive Leadership Team will continue to be led by CEO David Meek, and, in addition to the new CFO role, will comprise the following executives:

• Charles Baum, Ph.D, M.D., President, Founder and Head of Research & Development;
• James Christensen, Ph.D., Chief Scientific Officer;
• Reena Desai, General Counsel and Corporate Secretary;
• Kristin Gustafson, Chief Human Resources Officer;
• Ben Hickey, Chief Commercial Officer; and
• Vickie Reed, Chief Accounting Officer.

"On behalf of the Mirati team and the Board, we are grateful to both Dan and Joe for their invaluable contributions to bring the company to where it is today, and we wish them the best in their next endeavors," said Mr. Meek. "At Mirati, we have a deeply passionate team, an incredible scientific platform and a significant opportunity to improve patients' lives. It is imperative our leadership team structure best position us to execute on our mission as the company transitions from developing best-in-class therapies to also delivering them to patients living with cancer."

About Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc. is a clinical-stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. The company is relentlessly focused on bringing forward therapies that address areas of high unmet need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer. Mirati is using its scientific expertise to develop novel solutions in two registration-enabling programs: adagrasib (MRTX849), an investigational small molecule, potent and selective KRASG12C inhibitor, as monotherapy and in combination with other agents, and sitravatinib, an investigational spectrum-selective inhibitor of receptor tyrosine kinases in combination with checkpoint inhibitor therapies. Mirati is also advancing its differentiated preclinical portfolio, including MRTX1133, an investigational KRASG12D inhibitor, MRTX1719, an investigational PRMT5 inhibitor, and other oncology discovery programs. Unified for patients, Mirati's vision is to unlock the science behind the promise of a life beyond cancer.

For more information about Mirati Therapeutics Inc., visit us at Mirati.com or follow us on Twitter and LinkedIn. 

Forward Looking Statements

This statement contains forward-looking statements regarding the business of Mirati Therapeutics, Inc. ("Mirati"). Any statement describing Mirati's goals, expectations, financial or other projections, intentions or beliefs, development plans and the commercial potential of Mirati's drug development pipeline, including without limitation adagrasib (MRTX849), sitravatinib, MRTX1719 and MRTX1133, is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to risks and uncertainties, particularly those challenges inherent in the process of discovering, developing and commercialization of new drug products that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.

Mirati's forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Mirati's forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Mirati. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Mirati's programs are described in additional detail in Mirati's quarterly reports on Form 10-Q and annual reports on Form 10-K, which are on file with the U.S. Securities and Exchange Commission (the "SEC") available at the SEC's Internet site (www.sec.gov).These forward-looking statements are made as of the date of this press release, and Mirati assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

Mirati Contacts

Investor Relations: Temre Johnson | 858-332-3562 | [email protected]

Media Relations: Priyanka Shah | 908-447-6134 | [email protected]